MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Agios Pharmaceuticals Inc

Open

SectorGezondheidszorg

29.4 3.48

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

28.13

Max

29.49

Belangrijke statistieken

By Trading Economics

Inkomsten

-1B

-97M

Verkoop

1.7M

11M

K/W

Sectorgemiddelde

2.349

57.333

EPS

-1.74

Winstmarge

-899.562

Werknemers

486

EBITDA

-21M

-124M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+90.81% upside

Dividenden

By Dow Jones

Volgende Winsten

1 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-395M

1.6B

Vorige openingsprijs

25.92

Vorige sluitingsprijs

29.4

Technische score

By Trading Central

Vertrouwen

Very Strong Bullish Evidence

Agios Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

26 sep 2024, 14:20 UTC

Acquisities, Fusies, Overnames

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

Peer Vergelijking

Prijswijziging

Agios Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

90.81% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 55.83 USD  90.81%

Hoogste 74 USD

Laagste 43 USD

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor Agios Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

5

Buy

2

Hold

0

Sell

Technische score

By Trading Central

26.92 / N/ASteun & Weerstand

Korte Termijn

Very Strong Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.